FDA Approves Immunomedics' Breast Cancer Drug

On Wednesday the Food and Drug Administration granted accelerated approval to Immunomedics (NASDAQ: IMMU) for its antibody drug conjugate treatment for triple-negative breast cancer (TNBC). The treatment, which has the generic name sacituzumab govitecan, will be marketed by the company as Trodelvy. It's the first pharmaceutical to be approved for metastatic TNBC, and will be given to patients who have received two prior treatments for the disease.